MMP patients have a significantly increased risk of SCC, BCC, and NMSC, particularly with severe disease. The study analyzed data from over 117 million individuals, using propensity-score matching for ...
Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.
Longitudinal sections of inflorescence stems of wild type (WT) (left) and at2-mmp mutant (right) at 7 days after incision. Arrowheads indicate the position of incision. Scale bars, 100 μm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback